Partner Article

Durham University spin-out in deal to develop potential cancer test

FScan Ltd, a Durham University spin-out company, has signed a deal to enable the development of technology that could improve the diagnosis of prostate cancer in the future.

FScan Ltd has agreed a worldwide exclusive licensing deal with Glide Pharma which will see the Oxfordshire-based company exploit its technology that can be used to signal the onset and progression of prostate cancer.

The technology was developed by Professor David Parker and Dr Robert Pal working in Durham University’s Department of Chemistry, where David has been a Professor since 1992.

Dr Pal, a former Durham PhD student and a current Research Associate, is due to begin a prestigious Royal Society University Research Fellowship in October this year.

Kish Mistry, CEO of FScan Ltd, said: “We are delighted to have executed this agreement with Glide Pharma, as they are very well positioned to move this promising technology forward for the benefit of patients and clinicians in the prostate cancer field.”

To find out more, watch the video here: https://www.youtube.com/watch?v=l63HukYmz3A

This was posted in Bdaily's Members' News section by Ellen Forster .